Expert Insights: Evolving Treatment Landscape in NDMM

December 20, 2024

By Cristina Gasparetto, MD
Amandeep Godara, MBBS

Opinion

Video

Panelists discuss how the treatment paradigm for newly diagnosed multiple myeloma (NDMM) has evolved from conventional chemotherapy to modern regimens incorporating novel agents like proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies while highlighting persistent challenges including optimizing treatment sequencing and addressing high-risk disease.

Now Viewing

EP: 1.Expert Insights: Evolving Treatment Landscape in NDMM

EP: 2.Key Highlights From the PERSEUS and CASSIOPEIA Studies

EP: 3.ASH 2024 Updates —AURIGA: Daratumumab Plus Lenalidomide in Maintenance Post Transplant

EP: 4.Anti-CD38 Quadruplet Induction Regimens in TE NDMM: New Standard of Care

EP: 5.Clinical Perspectives: Selecting Between Daratumumab- and Isatuximab-Containing Quadruplet Induction Regimens

EP: 6.ASH 2024 Highlights: GMMG-HD7 Study

EP: 7.Where Are We Going? Future Perspectives on Navigating the Treatment Paradigm in Transplant-Eligible NDMM

EP: 8.Key Highlights: CEPHEUS Trial SubQ Dara-VRd vs VRd in Transplant-Eligible or Transplant-Deferred NDMM

EP: 9.Transplant-Ineligible NDMM: When to Use a Quadruplet Regimen

EP: 10.Expert Perspectives: Navigating Between CEPHEUS and IMROZ Studies

EP: 11.Challenges in Treating Frail Patients With NDMM: In the Real-World Practice: Potential Steroid-Free Regimens

EP: 12.Future Perspectives: What’s Next in NDMM?

EP: 13.Assessing CD38 Monoclonal Antibody-Based Regimens in NDMM

Video content above is prompted by the following:

Provide a brief historical overview of the therapeutic landscape for transplant-eligible and ineligible NDMM.
How has the landscape evolved since, and what challenges/unmet needs remain?

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!